Hu Yun-He, Li Ai-Dong
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
World J Clin Cases. 2024 Jul 16;12(20):4174-4179. doi: 10.12998/wjcc.v12.i20.4174.
Breast cancer is one of the most common malignant tumors in women worldwide and poses a severe threat to their health. Therefore, this study examined patients who underwent breast cancer surgery, analyzed hospitalization costs and structure, and explored the impact of China Healthcare Security Diagnosis Related Groups (CHS-DRG) management on patient costs. It aimed to provide medical institutions with ways to reduce costs, optimize cost structures, reduce patient burden, and improve service efficiency.
To study the CHS-DRG payment system's impact on breast cancer surgery costs.
Using the CHS-DRG (version 1.1) grouping criteria, 4073 patients, who underwent the radical resection of breast malignant tumors from January to December 2023, were included in the JA29 group; 1028 patients were part of the CHS-DRG payment system, unlike the rest. Through an independent sample -test, the length of hospital stay as well as total hospitalization, medicine and consumables, medical, nursing, medical technology, and management expenses were compared. Pearson's correlation coefficient was used to test the cost correlation.
In terms of hospitalization expenses, patients in the CHS-DRG payment group had lower medical, nursing, and management expenses than those in the diagnosis-related group (DRG) non-payment group. For patients in the DRG payment group, the factors affecting the total hospitalization cost, in descending order of relevance, were medicine and consumable costs, consumable costs, medicine costs, medical costs, medical technology costs, management costs, nursing costs, and length of hospital stay. For patients in the DRG non-payment group, the factors affecting the total hospitalization expenses in descending order of relevance were medicines and consumable expenses, consumable expenses, medical technology expenses, the cost of medicines, medical expenses, nursing expenses, length of hospital stay, and management expenses.
The CHS-DRG system can help control and reduce unnecessary medical expenses by controlling medicine costs, medical consumable costs, and the length of hospital stay while ensuring medical safety.
乳腺癌是全球女性中最常见的恶性肿瘤之一，对她们的健康构成严重威胁。因此，本研究对接受乳腺癌手术的患者进行了检查，分析了住院费用和结构，并探讨了中国医保疾病诊断相关分组（CHS-DRG）管理对患者费用的影响。其目的是为医疗机构提供降低成本、优化成本结构、减轻患者负担和提高服务效率的方法。
研究CHS-DRG支付系统对乳腺癌手术费用的影响。
采用CHS-DRG（1.1版）分组标准，将2023年1月至12月接受乳腺恶性肿瘤根治性切除术的4073例患者纳入JA29组；其中1028例患者纳入CHS-DRG支付系统，其余患者未纳入。通过独立样本检验，比较住院天数以及总住院费用、药品和耗材费用、医疗费用、护理费用、医疗技术费用和管理费用。采用Pearson相关系数检验费用相关性。
在住院费用方面，CHS-DRG支付组患者的医疗、护理和管理费用低于诊断相关组（DRG）非支付组患者。对于DRG支付组患者，影响总住院费用的因素按相关性从高到低依次为药品和耗材费用、耗材费用、药品费用、医疗费用、医疗技术费用、管理费用、护理费用和住院天数。对于DRG非支付组患者，影响总住院费用的因素按相关性从高到低依次为药品和耗材费用、耗材费用、医疗技术费用、药品费用、医疗费用、护理费用、住院天数和管理费用。
CHS-DRG系统可以在确保医疗安全的同时，通过控制药品费用、医疗耗材费用和住院天数，帮助控制和减少不必要的医疗费用。
